This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: November 20, 2009
Last updated: January 22, 2013
Last verified: January 2013
Efficacy and safety study of ABT-288 in adults with mild-to-moderate Alzheimer's disease.

Condition Intervention Phase
Alzheimer's Disease Drug: ABT-288 Drug: donepezil Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):

Primary Outcome Measures:
  • ADAS-cog: Alzheimer's Disease Assessment Scale - Cognition portion [ Time Frame: Screening Visit 1 & 2, Day -1, Weeks 4, 8 & 12/PD ]

Secondary Outcome Measures:
  • MMSE: Mini Mental Status Exam [ Time Frame: Screening Visit 1 & 2, Day -1, Weeks 4, 8 & 12/PD ]
  • NPI: Neuropsychiatric Inventory [ Time Frame: Day -1, Weeks 4,8, 12/PD ]
  • ADCS-ADL: Alzheimer's Disease Cooperative Study [ Time Frame: Day -1, Weeks 4,8 & 12/PD ]
  • CIBIC-Plus: Clinician Interview-Baed Impression of Change - plus [ Time Frame: Day -1, Weeks 4,8 & 12/PD] ]

Enrollment: 242
Study Start Date: December 2009
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1, Dose 1, ABT-288
Low Dose
Drug: ABT-288
Subjects will take 4 capsules once daily for 12 weeks.
Experimental: Arm 2, Dose 2, ABT-288
High dose
Drug: ABT-288
Subjects will take 4 capsules once daily for 12 weeks.
Active Comparator: donepezil Drug: donepezil
Subjects will take 4 capsules once daily for 12 weeks.
Other Name: Aricept
Placebo Comparator: sugar pill Drug: placebo
Subjects will take 4 capsules once daily for 12 weeks.


Ages Eligible for Study:   55 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Have voluntarily signed an informed consent.
  2. Subject meets diagnostic criteria criteria for probable AD (Alzheimer's Disease).
  3. Female subjects must be postmenopausal for at least 2 years or surgically sterile.
  4. Male subjects must be surgically sterile, sexually inactive or using a barrier method of birth control.
  5. Subject has an identified, reliable caregiver.
  6. Subject has a CT or MRI scan within 36 months prior to randomization.
  7. With the exception of a diagnosis of mild-to-moderate AD and the presence of stable medical conditions, the subject is generally in good health based on medical history, physical examination, vital signs, clinical lab tests and ECG

Exclusion Criteria:

  1. Subject is currently taking or has taken a medication for the treatment of AD or dementia with 60 days of Screening visit, or is participating in cognitive therapy for the treatment of AD or dementia.
  2. Subject uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence.
  3. Subject has a history of any significant neurologic disease other than AD.
  4. Subject has a history of intolerance or adverse reaction to donepezil that led to discontinuation.
  5. Subject has received any investigation product within 6 weeks prior to study drug administration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01018875

Russian Federation
Site Reference ID/Investigator# 22687
Kazan, Russian Federation, 420012
Site Reference ID/Investigator# 22636
Moscow, Russian Federation, 115522
Site Reference ID/Investigator# 23702
Moscow, Russian Federation, 123995
Site Reference ID/Investigator# 22689
Saratov, Russian Federation, 410060
Site Reference ID/Investigator# 22635
St. Petersburg, Russian Federation, 190005
Site Reference ID/Investigator# 22633
St. Petersburg, Russian Federation, 190103
Site Reference ID/Investigator# 22637
St. Petersburg, Russian Federation, 190121
Site Reference ID/Investigator# 22632
St. Petersburg, Russian Federation, 192019
Site Reference ID/Investigator# 22634
St. Petersburg, Russian Federation, 192019
Site Reference ID/Investigator# 24563
St. Petersburg, Russian Federation, 194044
Site Reference ID/Investigator# 22630
Dnipropetrovs'k, Ukraine, 49027
Site Reference ID/Investigator# 22625
Donetsk, Ukraine
Site Reference ID/Investigator# 22624
Glevakha, Ukraine, 08631
Site Reference ID/Investigator# 22629
Kharkiv, Ukraine, 61168
Site Reference ID/Investigator# 24565
Kherson, Ukraine, 73488
Site Reference ID/Investigator# 24566
Kiev, Ukraine, 04112
Site Reference ID/Investigator# 22622
Kiev, Ukraine, 04114
Site Reference ID/Investigator# 22623
Kiev, Ukraine, 05113
Site Reference ID/Investigator# 22628
Lugansk, Ukraine, 91045
Site Reference ID/Investigator# 43143
Odessa, Ukraine, 65006
Site Reference ID/Investigator# 22627
Poltava, Ukraine, 36006
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: George Haig AbbVie
  More Information

Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01018875     History of Changes
Other Study ID Numbers: M10-822
2009-010704-29 ( EudraCT Number )
Study First Received: November 20, 2009
Last Updated: January 22, 2013

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents processed this record on August 17, 2017